Cargando…

Will drug resistance against dolutegravir in initial therapy ever occur?

Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More interestingly, clinical resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wainberg, Mark A., Han, Ying-Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413831/ https://www.ncbi.nlm.nih.gov/pubmed/25972810 http://dx.doi.org/10.3389/fphar.2015.00090

Ejemplares similares

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
por: Wainberg, Mark A, et al.
Publicado: (2015)

HIV–1 resistance to dolutegravir: update and new insights
por: Wainberg, Mark A, et al.
Publicado: (2015)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

Design, synthesis and antitumour activity evaluation of novel dolutegravir derivatives
por: Hou, Xi-Xi, et al.
Publicado: (2023)

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
por: Kouamou, Vinie, et al.
Publicado: (2023)

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
por: Mesplède, Thibault, et al.
Publicado: (2013)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
por: Mesplède, Thibault, et al.
Publicado: (2018)

The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!
por: Tagoe, Daniel N. A., et al.
Publicado: (2015)

Does Acute General Dropsy Ever Occur as an Idiopathic Disease?
por: Goldsberry, J. A.
Publicado: (1878)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
por: Saha, Rudra P., et al.
Publicado: (2020)

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
por: dos Santos, Thaiane Coelho, et al.
Publicado: (2018)

Drug reprofiling history and potential therapies against Parkinson’s disease
por: Latif, Komal, et al.
Publicado: (2022)

Identification of naturally occurring inhibitors in Xian-Ling-Gu-Bao capsule against the glucuronidation of estrogens
por: He, Liangliang, et al.
Publicado: (2022)

Editorial: The pharmacological effects and mechanisms of drugs against human diseases by modulating redox homeostasis
por: Zhang, Ying, et al.
Publicado: (2023)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

Combination Therapy Strategies Against Multiple-Resistant Streptococcus Suis
por: Yu, Yang, et al.
Publicado: (2018)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Antibacterial Activity and Mechanism of Action of Aspidinol Against Multi-Drug-Resistant Methicillin-Resistant Staphylococcus aureus
por: Hua, Xin, et al.
Publicado: (2018)

In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis
por: Marquês, Joaquim Trigo, et al.
Publicado: (2022)

Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
por: Nagami, Ellen H, et al.
Publicado: (2021)

The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance
por: Chen, Zhaolin, et al.
Publicado: (2022)

Editorial: Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies
por: Zhou, Fanfan, et al.
Publicado: (2022)

Interactions of different drug resistance mutations in HIV Reverse Transcriptase in defining patterns of drug resistance
por: Wainberg, Mark A
Publicado: (2011)

Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens
por: Hind, Charlotte K., et al.
Publicado: (2019)

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
por: DeAnda, Felix, et al.
Publicado: (2013)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

The slippery difficulty of ever containing drug resistance with current practices
por: Fullybright, R.
Publicado: (2016)

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis
por: Wandeler, Gilles, et al.
Publicado: (2019)

Curcumae Rhizoma: A botanical drug against infectious diseases
por: Wu, Ying-Qi, et al.
Publicado: (2023)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

Cardioprotective Action of Ginkgo biloba Extract against Sustained β-Adrenergic Stimulation Occurs via Activation of M(2)/NO Pathway
por: Mesquita, Thássio R. R., et al.
Publicado: (2017)

Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives
por: Tan, Hui-Li, et al.
Publicado: (2016)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j69chk96qcfo47pskb9gpoeak1